264 related articles for article (PubMed ID: 9252706)
21. [Clinical evaluation of tumor markers in patients with colorectal cancer].
Naritaka Y; Ogawa K; Matsumoto N; Hosokawa T; Kikuchi T; Koyama N; Haga S; Kajiwara T; Sakakibara N
Gan No Rinsho; 1987 Aug; 33(10):1274-80. PubMed ID: 2444727
[TBL] [Abstract][Full Text] [Related]
22. [Tumor markers in patients with head-neck carcinomas].
Walther EK; Dahlmann N; Gorgulla HT
Laryngorhinootologie; 1990 May; 69(5):271-4. PubMed ID: 2354022
[TBL] [Abstract][Full Text] [Related]
23. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease.
Engarås B; Kewenter J; Nilsson O; Wedel H; Hafström L
Eur J Surg Oncol; 2001 Feb; 27(1):43-8. PubMed ID: 11237491
[TBL] [Abstract][Full Text] [Related]
24. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
[TBL] [Abstract][Full Text] [Related]
25. Significance of CA72.4 in patients with colorectal cancer. Comparison with CEA and CA19.9.
Filella X; Molina R; Mengual PJ; Jo J; Ballesta AM
J Nucl Biol Med (1991); 1991; 35(3):158-61. PubMed ID: 1816871
[TBL] [Abstract][Full Text] [Related]
26. [Clinical evaluation of a combination assay of CEA, CA-19-9 and TPA in patients with colorectal cancer].
Nishida O; Shiroto H; Satoh N; Nakajima Y; Manabe K; Kondoh Y; Sano F; Uchino J
Gan No Rinsho; 1988 Aug; 34(9):1096-100. PubMed ID: 3172515
[TBL] [Abstract][Full Text] [Related]
27. [The monitoring of gynecological radiotherapy using serial tumor marker determinations].
Wagner RK; Atzinger A; Breit A
Strahlenther Onkol; 1990 Jul; 166(7):446-52. PubMed ID: 2200151
[TBL] [Abstract][Full Text] [Related]
28. Application of tumor markers CEA, TPA, and SCC-Ag in patients with low-risk FIGO stage IB and IIA squamous cell carcinoma of the uterine cervix.
Juang CM; Wang PH; Yen MS; Lai CR; Ng HT; Yuan CC
Gynecol Oncol; 2000 Jan; 76(1):103-6. PubMed ID: 10620449
[TBL] [Abstract][Full Text] [Related]
29. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
30. Tumor markers in patients with relapse of colorectal carcinoma.
Lipská L; Visokai V; Levý M; Svobodová S; Kormunda S; Fínek J
Anticancer Res; 2007; 27(4A):1901-5. PubMed ID: 17649792
[TBL] [Abstract][Full Text] [Related]
31. [Clinical evaluation of four tumor markers (CEA, TPA, CA50 and CA72-4) in colorectal cancer].
Koizumi F; Odagiri H; Fujimoto H; Kawamura T; Ishimori A
Rinsho Byori; 1992 May; 40(5):523-8. PubMed ID: 1507478
[TBL] [Abstract][Full Text] [Related]
32. CEA, TPA, CA 19-9, SCC and CYFRA at diagnosis and in the follow-up of anal canal tumors.
Indinnimeo M; Reale MG; Cicchini C; Stazi A; Fiori E; Izzo P
Int Surg; 1997; 82(3):275-9. PubMed ID: 9372374
[TBL] [Abstract][Full Text] [Related]
33. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients.
Nakagoe T; Sawai T; Tsuji T; Jibiki MA; Nanashima A; Yamaguchi H; Yasutake T; Ayabe H; Arisawa K
Hepatogastroenterology; 2003; 50(51):696-9. PubMed ID: 12828063
[TBL] [Abstract][Full Text] [Related]
34. [Tumor markers in gastrointestinal cancer and its clinical significance].
Taguchi T; Ota J; Sumida S; Rii M
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3004-9. PubMed ID: 3479051
[TBL] [Abstract][Full Text] [Related]
35. [Expression of tumor-associated antigen LEA and its significance for pathological diagnosis].
Feng H; Song JD
Ai Zheng; 2002 Jun; 21(6):658-62. PubMed ID: 12452070
[TBL] [Abstract][Full Text] [Related]
36. A comparative analysis of the serum levels of NCC-ST-439, CEA and CA19-9 in patients with colorectal carcinoma.
Iemura K; Moriya Y
Eur J Surg Oncol; 1993 Oct; 19(5):439-42. PubMed ID: 8405479
[TBL] [Abstract][Full Text] [Related]
37. Serum tumour markers in patients with chronic kidney disease.
Xiaofang Y; Yue Z; Xialian X; Zhibin Y
Scand J Clin Lab Invest; 2007; 67(6):661-7. PubMed ID: 17852811
[TBL] [Abstract][Full Text] [Related]
38. Serum tumor markers.
Perkins GL; Slater ED; Sanders GK; Prichard JG
Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
[TBL] [Abstract][Full Text] [Related]
39. CA19-9 as the most significant prognostic indicator of metastatic colorectal cancer.
Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Wang HS; Chen PM
Hepatogastroenterology; 2002; 49(43):160-4. PubMed ID: 11941943
[TBL] [Abstract][Full Text] [Related]
40. Clinical evaluation of serum and immunohistochemical expression of SCC and CA19-9 in radiation therapy for cervical cancer.
Abe A; Nakano T; Morita S; Oka K
Anticancer Res; 1999; 19(1B):829-36. PubMed ID: 10216501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]